Houssein Abdul Sater, M.D.
Dr. Sater is a translational physician scientist (hematologist/oncologist) with special interest in immune therapy of cancer. He leads the Genitourinary Malignancies Branch efforts at understanding the role of cancer immunotherapy on the tumor (immune and non-immune) micro-environment. Dr Sater is one of the few nationally recognized experts in tissue-based multiplex biomarker development and multispectral imaging. The Society of Immune Therapy of Cancer (SITC) chose him as one of 29 young leader investigators to tackle one of the major hurdles in immune therapy in a funded consortium effort (Sparkathon Timios Project). He also has an interest in demographics (gender, race, age, BMI) effect on immune therapy as a biomarker for better personalized medicine.
1) immunotherapy of cancer, 2) immunopathology, 3) multispectal imaging, 4) clinical trial design, 5) biomarker development
Dr. Sater is a pan-tumor immuno-oncologist and research pathologist. His laboratory research is focused on understanding the role of cancer immunotherapy on the tumor (immune and non-immune) micro-environment with advanced multiplex assays and multispectral imaging. These advanced technologies enable the use of precious patient samples sparingly, multiplexing multiple antibodies on a single slide. He works closely with different CCR collaborators and the Laboratory of Tumor Immunology and Biology to translate preclinical findings into innovative clinical trials.
Selected Key Publications
Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University's lung cancer patients.Int J Gen Med. 7: 333–337, 2014. [ Journal Article ]
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer..Oncologist. 2019-0608: 2019. [ Journal Article ]
- Journal of Biological Chemistry 294.14 . 14: 5246-5260., 2019. [ Journal Article ]
- NPJ breast cancer. 5/1: Nature Publishing Group 1 - 13, 2019. [ Journal Article ]
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.Journal for ImmunoTherapy of Cancer. 8/1: BMJ Specialist Journals e000655, 2020. [ Journal Article ]
Dr Sater is a nationally recognized expert in tumor immuno-pathology. He graduated from the Lebanese University School of Medicine in Lebanon with an M.D. in 2007 followed by a surgical pathology residency. Dr. Sater then completed his residency in internal medicine at Northshore LIJ system (Northwell Hospital, NY) in 2014, followed by a medical hematology/oncology fellowship at Augusta University, GA. In addition to training as a translational immunotherapist, he focused on understanding immune therapy effect on tumor immune and non-immune microenvironment in prostate, breast and lung cancer using advanced molecular and imaging techniques. Dr. Sater received several awards including a 2-year onco-pathology FOSFOM scholarship in Belgium and the SPARKATHON project award by the Society of Immune Therapy of Cancer. Dr. Sater has authored different journal articles and book chapters, and has given several invited presentations at national meetings.